Prevalence of aspirin sensitivity in moderate to severe asthma according to the response to 3 months asthma standard therapy

Prevalence of aspirin sensitivity in patients with moderate to severe asthma according to the response to 3 months asthma standard therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015042721970N1

Enrollment

100

Registered

2015-07-29

Start date

2015-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Mixed asthma Combination of conditions listed in J45.0 and J45.1

Interventions

Standard treatment of moderate to severe asthma based on EPR-3 guidelines, include inhaled corticosteroids, inhaled long acting bronchodilators(for moderate asthma: Fluticasone-Salmeterol 250/50 micro

Treatment - Drugs

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 18 to 65 years old; moderate to severe asthma according to the history and spirometric findings and EPR-3 (Expert Panel Report 3) guidelines Exclusion criteria: Presence of serious underlying disease such as bleeding disorders, gastrointestinal, rheumatologic, cancer, heart, kidney, liver and mental diseases; medical history of immediate hypersensitivity reactions to aspirin and nonsteroidal anti-inflammatory drugs; Forced Expiratory Volume in the first second (FEV1) less than 70% at the time of aspirin challenge; pregnancy; breast-feeding; the use of systemic and topical beta-blocker, angiotensin-converting enzyme inhibitor, angiotensinogen ? receptor blocker, warfarin; mastocytosis; nonadherent patients; patients with high risk jobs or lifestyle

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Asthma symptoms. Timepoint: At first and after 3 months of study. Method of measurement: Standard questionnaire "Asthma Control Test".;Pulmonary function. Timepoint: At first and after 3 months of study. Method of measurement: Spirometry test.	—

Secondary

Measure	Time frame
Asthma standard treatment side effect: mouth thrush. Timepoint: Monthly. Method of measurement: Questionair.;Asthma standard treatment side effect: hoarseness. Timepoint: Monthly. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Narges Eslami

Allergy and clinical immunology department of Rasool Akram hospital

drnarges@yahoo.com+98 21 6435 2383

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026